Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

April 2013

Clinical Trials, Cohort Studies, Pilot Studies

Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients. Huang CF, Dai CY, Yeh ML, et al. PLoS One. 2013;8(3):e58882. doi: 10.1371/journal.pone.0058882. Epub 2013 Mar 19.

http://www.ncbi.nlm.nih.gov/pubmed/23527043

Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. Itokawa N, Atsukawa M, Tsubota A, et al. J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039.

http://www.ncbi.nlm.nih.gov/pubmed/23173698

Patterns of Interferon-alpha Induced Thyroid Dysfunction Vary with Ethnicity, Sex, Smoking Status and Pre-Treatment TSH in an International Cohort of Patients Treated for Hepatitis C. Mammen JS, Ghazarian SR, Rosen A, Ladenson PW. Thyroid. 2013 Mar 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23517287

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Kowdley KV, Lawitz E, Crespo I, et al. Lancet. 2013 Mar 14. pii: S0140-6736(13)60247-0. doi: 10.1016/S0140-6736(13)60247-0. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23499440

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lawitz E, Lalezari JP, Hassanein T, et al. Lancet Infect Dis. 2013 Mar 14. pii: S1473-3099(13)70033-1. doi: 10.1016/S1473-3099(13)70033-1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23499158

Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans with Chronic Hepatitis C. Belperio PS, Hwang EW, Thomas IC, Mole LA, Cheung R, Backus LI. Clin Gastroenterol Hepatol. 2013 Mar 20. pii: S1542-3565(13)00385-6. doi: 10.1016/j.cgh.2013.03.006. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23524130

Management of Hepatitis C Virus Infection in Heavy Drinkers. Costentin CE, Trabut JB, Mallet V, et al. Alcohol Alcohol. 2013 Mar 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23518789

Basic and Applied Science, Pre-Clinical Studies

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. McPhee F, Hernandez D, Yu F, et al. Hepatology. 2013 Mar 15. doi: 10.1002/hep.26388. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23504694

Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus.

Tayel SS, Helmy AA, Ahmed R, Esmat G, Hamdi N, Abdelaziz AI. Arch Virol. 2013 Mar 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23525700

Natural Killer Cell Dynamic Profile Is Associated with Treatment Outcome in Patients with Chronic HCV Infection. Oliviero B, Mele D, Degasperi E, et al. J Hepatol. 2013 Mar 13. pii: S0168-8278(13)00152-9. doi: 10.1016/j.jhep.2013.03.003. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23499727

Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection. Stinton LM, Myers RP, Coffin CS, Fritzler MJ. BMC Gastroenterol. 2013 Mar 19;13:50. doi: 10.1186/1471-230X-13-50.

http://www.ncbi.nlm.nih.gov/pubmed/23506439

Hepatitis C virus core protein induces hepatic metabolism disorders through down-regulation of the SIRT1-AMPK signaling pathway. Yu JW, Sun LJ, Liu W, Zhao YH, Kang P, Yan BZ. Int J Infect Dis. 2013 Mar 16. pii: S1201-9712(13)00079-9. doi: 10.1016/j.ijid.2013.01.027. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23510538

HIV/HCV Coinfection

Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin. Webster DP, Wojcikiewicz T, Keller M, et al. Int J STD AIDS. 2013 Mar 20. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23514835

Current management of hepatitis C virus infection in patients with HIV co-infection. Sulkowski MS. J Infect Dis. 2013 Mar;207 Suppl 1:S26-32. doi: 10.1093/infdis/jis764.

http://www.ncbi.nlm.nih.gov/pubmed/23390302

Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections. Schlatzer DM, Sugalski JM, Chen Y, et al. J Acquir Immune Defic Syndr. 2013 Mar 15. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23507661

Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus-Coinfected Patients With Compensated Cirrhosis. Mira JA, Rivero-Juárez A, López-Cortés LF, et al. Clin Infect Dis. 2013 Mar 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23429381

Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions. Winnock M, Bani-Sadr F, Pambrun E, et al. HIV Med. 2013 Mar 5. doi: 10.1111/hiv.12023. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23461846

Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection. Peribañez-Gonzalez M, da Silva MH, Vilar FC, et al. Ann Hepatol. 2013 Mar;12(2):228-35.

http://www.ncbi.nlm.nih.gov/pubmed/23396734

Complementary and Alternative Medicine

Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea.

Steinmann J, Buer J, Pietschmann T, Steinmann E. Br J Pharmacol. 2013 Mar;168(5):1059-73. doi: 10.1111/bph.12009.

http://www.ncbi.nlm.nih.gov/pubmed/23072320

Epidemiology, Diagnostics, and Miscellaneous Works

Prevalence and predictors of hepatitis B virus co-infection in a United States cohort of hepatitis C virus-infected patients. Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Hepatology. 2013 Mar 16. doi: 10.1002/hep.26400. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23505059

The Diagnostic Accuracy of Fibroscan for Cirrhosis is Influenced by Liver Morphometry in HCV Patients with a Sustained Virological Response. D'Ambrosio R, Aghemo A, Fraquelli M, et al. J Hepatol. 2013 Mar 22. pii: S0168-8278(13)00191-8. doi: 10.1016/j.jhep.2013.03.013. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23528378

Assessment and utilization of rapid virologic response in US veterans with chronic hepatitis C: evaluating provider adherence to practice guidelines. Hwang EW, Thomas IC, Cheung R, Backus LI. J Clin Gastroenterol. 2013 Mar;47(3):264-70. doi: 10.1097/MCG.0b013e31827035cf.

http://www.ncbi.nlm.nih.gov/pubmed/23269309

Cost-Effectiveness of Screening for Chronic Hepatitis C Infection in the United States.

Eckman MH, Talal AH, Gordon SC, Schiff E, Sherman KE. Clin Infect Dis. 2013 Mar 5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23392392

Important Factors in Reliable Determination of Hepatitis C Virus Genotype using the 5' Untranslated Region. Hara K, Rivera MM, Koh C, Sakiani S, Hoofnagle JH, Heller T. J Clin Microbiol. 2013 Mar 6. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23467599

Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance. Kuwashiro T, Mizuta T, Kawaguchi Y, et al. J Gastroenterol. 2013 Mar 16. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23503838

Birth Cohort Screening for Chronic Hepatitis During Colonoscopy Appointments.

Sears DM, Cohen DC, Ackerman K, Ma JE, Song J. Am J Gastroenterol. 2013 Mar 19. doi: 10.1038/ajg.2013.50. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23511461

Diagnostic difficulties, therapeutic strategies, and performance of scoring systems in patients with autoimmune hepatitis and concurrent hepatitis B/C. Efe C, Wahlin S, Ozaslan E, et al. Scand J Gastroenterol. 2013 Apr;48(4):504-8. doi: 10.3109/00365521.2013.772231. Epub 2013 Mar 1.

http://www.ncbi.nlm.nih.gov/pubmed/23448312

Safety aspects of protease inhibitors for chronic hepatitis C: Adverse events and drug-to-drug interactions. Teixeira R, Nascimento YD, Crespo D. Braz J Infect Dis. 2013 Mar 8. pii: S1413-8670(13)00021-4. doi: 10.1016/j.bjid.2012.10.010. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23490868

Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Lubega S, Agbim U, Surjadi M, Mahoney M, Khalili M. Liver Int. 2013 Mar 7. doi: 10.1111/liv.12150. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23509897

A Survey of Hepatitis C Treatment Clinical Practice Patterns Using the Newly Approved Protease Inhibitors. Chen EY, Lee WM, Hynan LS, Singal AG. J Clin Gastroenterol. 2013 Mar 6. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23470640

Liver Cancer

Global Gene Expression Profiling Reveals SPINK1 as a Potential Hepatocellular Carcinoma Marker. Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. PLoS One. 2013;8(3):e59459. doi: 10.1371/journal.pone.0059459. Epub 2013 Mar 18.

http://www.ncbi.nlm.nih.gov/pubmed/23527199

Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. J Clin Oncol. 2013 Mar 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23509319

Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. Kim MN, Kim BK, Han KH. J Gastroenterol. 2013 Mar 6. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23463401

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. Sangro B, Gomez-Martin C, de la Mata M, et al. J Hepatol. 2013 Mar 2. pii: S0168-8278(13)00144-X. doi: 10.1016/j.jhep.2013.02.022. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23466307

Serum VEGF as a Tumor Marker in Patients with HCV-related Liver Cirrhosis and Hepatocellular Carcinoma. Mukozu T, Nagai H, Matsui D, Kanekawa T, Sumino Y. Anticancer Res. 2013 Mar;33(3):1013-21.

http://www.ncbi.nlm.nih.gov/pubmed/23482775